The strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for ...

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Companies sometimes miss the mark when it comes to telling employees they’re out of a job. From accidental goodbyes to ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL trial and promised to share more at an upcoming scientific meeting.